{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106924","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.769368+00:00","generated_at":"2026-05-17T14:41:18.960610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mereo BioPharma Q2 net loss $14.6M; setrusumab Phase 3 data due year-end 2025","bullets":["Net loss of $14.6M in Q2 2025 vs $12.3M in Q2 2024; cash $56.1M as of June 30, 2025.","Phase 3 Orbit and Cosmic studies of setrusumab in OI on track for final analysis around year-end 2025.","DMC interim analysis in July 2025 confirmed acceptable safety for setrusumab; study continues to final analysis.","R&D expenses $5.4M (+$0.4M YoY) driven by setrusumab manufacturing; G&A down $2.4M to $5.5M.","Alvelestat partnering discussions ongoing; cash expected to fund operations into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106924","json":"https://secwatch.observer/filing/0000950170-25-106924.json","markdown":"https://secwatch.observer/filing/0000950170-25-106924.md","text":"https://secwatch.observer/filing/0000950170-25-106924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/0000950170-25-106924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/mreo-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:41:18.960610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}